Two biometrics proposals land in the same week for the same Phase II study. One is noticeably cheaper.

Read them side by side and the gap starts to explain itself. The cheaper bid assumes one interim analysis instead of two. It prices tables, listings, and figures as a flat count with no distinction between unique and repeat outputs. It validates outputs by review instead of independent double programming. And it says nothing about define.xml or reviewer’s guides.

Neither bid is wrong. They are pricing different studies.

That is the core problem with buying clinical biostatistics services. The pricing model matters, but the assumptions underneath it matter more. This guide breaks down the common biometrics CRO pricing models, the line items that actually drive cost, and how to compare bids so the number you approve is the number you pay.

What Clinical Biostatistics Services Include in a Biometrics Budget

“Biometrics” usually bundles three disciplines: biostatistics, statistical programming, and often clinical data management. Each carries its own units of work, and a budget is only as clear as its breakdown of them.

Submission work is where bids diverge most. FDA requires standardized study data for NDAs, BLAs, ANDAs, and commercial INDs, and lists CDISC SDTM and ADaM among its supported standards. A proposal that prices SDTM and ADaM without define.xml, the CDISC metadata standard that describes submitted datasets, is quoting a partial deliverable.

If the scope table in a proposal is shorter than this one, ask what’s missing.

The Common Biometrics CRO Pricing Models Compared

Most biometrics pricing falls into one of five structures. Each shifts risk between you and the CRO in a different way.

Fixed Price

A fixed price looks like certainty. It’s only as certain as the assumptions in the scope.

Every fixed-price biometrics proposal rests on a list of assumptions: number of TLFs, number of datasets, number of data transfers, number of SAP versions, number of review cycles. Change any of them and a change order follows.

Fixed price works well for a study with a final protocol, a stable design, and a clear output list. It works poorly when the protocol is still moving.

Unit-Based Pricing

Unit-based pricing makes the assumptions visible. You see a rate per unique table, per repeat table, per ADaM dataset, per dry run.

The detail to check is how “unit” is defined. A unique TLF (new programming) and a repeat TLF (same program, different population or timepoint) take very different effort. So do a simple listing and a complex efficacy table with modeling. A bid that prices all outputs at one rate is either padded or underpriced.

Time and Materials

T&M billing charges for actual hours. It suits early design work, consulting, and ad hoc analyses where nobody can honestly estimate the effort in advance.

For a full study, T&M without caps or regular burn reporting leaves you carrying all the risk. Pair it with monthly reporting against an estimate.

FTE or Dedicated Resource Models

In an FTE model, you pay for named statisticians and programmers dedicated to your program, often at a monthly rate. It suits sponsors running several studies on one compound, where continuity and institutional knowledge matter.

The risk is utilization. If your studies slow down, you pay for capacity you aren’t using.

Hybrid Models

Most real contracts are hybrids. A fixed or unit-based core covers predictable work such as SDTM, ADaM, and TLFs. T&M covers what’s hard to predict: ad hoc analyses, regulatory questions, post-hoc requests.

A hybrid is only as good as its boundary. Get the boundary in writing: which activities sit in the fixed core, and which trigger hourly billing.

The Line Items That Decide the Real Cost

Pricing models describe how you pay. These line items decide how much.

Two of these deserve more attention than they usually get.

Validation level is a quality decision disguised as a cost line. Independent double programming, where a second programmer writes separate code and the outputs are compared, is common practice for primary efficacy and key safety outputs. Cutting it saves money on paper. It also removes one of the few checks that catches a derivation error before it reaches a regulator.

SAP revisions cost more than they look. ICH E9 expects the statistical analysis plan to be finalized before the blind is broken, and blind data review often prompts changes. Each change can touch ADaM specifications, programs, and shells. A bid that assumes one SAP version is assuming a study that rarely exists.

Why Change Orders Happen, and How to See Them Coming

A change order is the price of an assumption that didn’t hold.

The most common triggers in biometrics work:

• Protocol amendments that add endpoints, visits, or populations
• More TLFs than assumed, usually after sponsor review of shells
• Extra data transfers or dry runs because data arrived late or messy
• An added interim analysis or DMC meeting
• Submission scope added late, such as define.xml or a second regulator’s requirements

Most of these are visible at contract stage if you read the assumptions page as carefully as the price.

A practical habit: before signing, list every assumption in the proposal and mark each one as confident, likely to change, or unknown. The second and third columns are your change order forecast.

What You Can’t Outsource: Oversight Is Part of the Cost

Outsourcing biometrics moves the work. Responsibility stays with you.

Under 21 CFR 312.52, a sponsor may transfer any or all of its obligations to a contract research organization, and any such transfer must be described in writing. ICH E6(R3), published by FDA as final guidance in September 2025, goes further: activities transferred to a service provider should be documented in an agreement, the sponsor should ensure appropriate oversight of important transferred activities, and ultimate responsibility stays with the sponsor.

That has a budget consequence. Somebody on your side has to:

1. Review and approve the SAP and table shells
2. Review key outputs, especially primary efficacy and safety
3. Track deliverables, burn, and change orders against the contract

If your team has no statistician, that oversight still has to come from somewhere, often an independent consultant. Put it in the budget next to the CRO’s fee.

Payment Milestones: When the Money Moves

How a biometrics contract is paid matters almost as much as how it is priced. Fixed-price and hybrid contracts are usually billed on milestones, and the choice of milestones shapes incentives on both sides.

Typical biometrics milestones include:

• SAP finalization
• Table shells approved
• SDTM and ADaM specifications approved
• First dry run delivered
• Final TLFs delivered after database lock
• Submission package delivered

Watch for two patterns. A schedule that front-loads payment before any programming is delivered leaves you little leverage if timelines slip. A schedule that pays mostly at the end can push the CRO to understaff the early, unglamorous work, such as specifications and shells, that prevents problems at lock.

A balanced schedule ties each payment to a deliverable you can review and approve.

How to Compare Biometrics CRO Bids Line by Line

Staffing is worth one more question. A bid priced on a senior statistician’s involvement but delivered mostly by junior programmers is a different product at the same price. Ask what percentage of hours each role carries.

Frequently Asked Questions

Q. What pricing models do biometrics CROs use?

Biometrics CROs typically use fixed-price, unit-based, time-and-materials, FTE or dedicated-resource, and hybrid pricing models. Most studies end up on a hybrid, with predictable programming work on a fixed or unit basis and variable work such as ad hoc analyses billed on time and materials.

Q. Is fixed-price or time-and-materials better for clinical biostatistics services?

Fixed price suits studies with a final protocol and a stable, well-defined output list. Time and materials suits early design work, consulting, and analyses whose effort can’t be estimated in advance. For a full study, a hybrid with a clear boundary between the two usually works best.

Q. What drives the cost of statistical programming in a clinical trial?

The main drivers are the number of unique versus repeat TLFs, the number of SDTM and ADaM datasets, the validation approach, the number of data transfers and dry runs, interim analyses, and submission deliverables such as define.xml and reviewer’s guides.

Q. Why do biometrics CRO projects generate change orders?

Change orders happen when the assumptions behind the price stop holding. Common triggers include protocol amendments, more TLFs than assumed, extra data transfers, added interim analyses, and submission scope that was not in the original contract.

Most are predictable from the assumptions page at contract stage.

Q. How should sponsors compare biostatistics CRO proposals?

Give every bidder the same scope and assumptions list, then compare each work stream separately. Check how units are defined, confirm the validation level, read the change order terms, and ask who will actually do the work.

Conclusion

The price on a biometrics proposal is a summary of its assumptions. Clinical biostatistics services priced on the same model can still cost very different amounts once TLF counts, validation levels, SAP revisions, and submission scope are laid side by side. Weltrix provides biostatistics, statistical programming, and CDISC dataset services, and the same test applies to any proposal you receive, Weltrix’s included: read the assumptions page first. It’s the page your change orders will come from.

Key Takeaways

• Biometrics bids differ mostly in their assumptions, not their pricing model.
• Fixed price moves effort risk to the CRO but leaves change order risk with you; time and materials leaves all risk with you.
• Unique vs repeat TLFs, validation level, data transfers, interim analyses, and submission scope are the biggest cost drivers.
• Define.xml and reviewer’s guides are real deliverables and should be priced explicitly.
• Under 21 CFR 312.52 and ICH E6(R3), sponsors can transfer biometrics work but keep ultimate responsibility, so oversight belongs in the budget.
• Normalizing bids against one scope and assumptions list is the only fair way to compare them.